First-in-class dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. Approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). Provides superior glycemic control and weight loss vs monotherapy.
Agonist at both GLP-1 and GIP receptors, enhancing glucose-dependent insulin secretion, improving beta-cell function, suppressing glucagon, slowing gastric emptying, and promoting satiety. Dual action provides greater efficacy than GLP-1 alone.
Agonist at both GLP-1 and GIP receptors, enhancing glucose-dependent insulin secretion, improving beta-cell function, suppressing glucagon, slowing gastric emptying, and promoting satiety. Dual action provides greater efficacy than GLP-1 alone.
© 2025[current_year] The Doctors Platform. All Right Reserved.
© 2025 The Doctors Platform. All Right Reserved.
